# Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

> **NCT03765671** · PHASE1 · COMPLETED · sponsor: **Genfit** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Impairment
- Liver Disease
- Pharmacokinetics

## Interventions

- **DRUG:** Elafibranor

## Key facts

- **NCT ID:** NCT03765671
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2019-06-07
- **Final completion:** 2019-06-14
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765671, "Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03765671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*